June 26-28, 2018

Frankfurt, Germany

Speakers

Expand/Collapse

Asha Das
Senior Vice President & Chief Medical Officer
Tocagen

Day One

Wednesday 27th June, 2018

12.40 | Retroviral Replicating Vectors for Armed Oncolytic Immunovirotherapy

Kah Whye Peng
CTO & Co-founder
Vyriad

Dr. Peng is Chief Technical Officer of Vyriad, Professor of Oncology and Director of the Pharmacology and Toxicology Laboratory in the Department of Molecular Medicine at Mayo Clinic. She is a Council Member and President Elect (USA) of the International Society of Cell and Gene Therapy and serves on numerous NIH grant review panels. She obtained her BSc degree (First Class Honors) in Zoology from the National University of Singapore and her PhD degree in Gene Therapy from the University of Cambridge, United Kingdom. Her research focuses on the development of new oncolytic virotherapies, reporter gene imaging of virus, gene and cell therapies, and to advance the most promising technologies to clinical testing.

Day Two

Thursday 28th June, 2018

12.10 | Systemic Cancer Therapy Using Oncolytic VSVs: The Voyager Platform

11.10 | Panel Discussion: Explore Novel Approaches to Identify the Most Rational Combinations

Talia Biran
VP, Clinical Development and Medical Affairs,
Oncolys USA

Talia Biran joined Oncolys USA in 2017, with over 25 years of experience in Medical affairs. Having worked at Janssen, Merck and Novartis, she contributed to the development and launch of Abiraterone Acetate (Zytiga ®, prostate cancer), Vorinostat (Zolinza®, CTCL), Letrozole (Femara®, breast cancer) and Octreotide (Sandostatin LAR®, neuroendocrine tumors (NETs) and acromegaly) Prior to Oncolys, Talia played a pivotal role at Lexicon Pharmaceuticals as Executive Director, where she established the US medical affairs infrastructure for Oncology and Diabetes programs and led the development and launch of Lexicon's first drug candidate, Telotristat Ethyl ( Xermelo, ® Carcinoid Syndrome Diarrhea) (Licensed Ex-US to Ipsen Inc) Talia holds a Master of Science (M.Sc) in Microbiology from Tel-Aviv University, Department of Life Sciences, in Tel-Aviv, Israel. Her thesis, under the supervision of Professor Sara Lavi, focused on Gene Amplification of SV-40 and its link to tumorigenesis.

Pre-Conference Workshop Day

Tuesday 26th June, 2018

13.00 | Novel Forms of Delivery for Oncolytic Immunotherapies

Jing Qing
Global Discovery Research Lead for IMLYGIC
Amgen

Day Two

Thursday 28th June, 2018

11.10 | Panel Discussion: Explore Novel Approaches to Identify the Most Rational Combinations

09.10 | Mechanisms of IMLYGIC, the Bedside to Bench Learning Loop

Jung-Joon Min
Professor & Chair, Department of Nuclear Medicine
Chonnam National University Medical School

Day One

Wednesday 27th June, 2018

16.10 | Engineered Salmonella typhimurium for Enhancement of Anti-Cancer Immunity

Frank Tufaro
Chief Executive Officer
DNAtrix

Day One

Wednesday 27th June, 2018

09.00 | Chair’s Opening Remarks

Day Two

Thursday 28th June, 2018

15.10 | Chair’s Closing Remarks

14.40 | Biomarkers to Track and Measure Clinical Efficacy

09.00 | Chair’s Opening Remarks

Frederick Lang
Professor & Chair of Clinical Research, Department of Neurosurgery
MD Anderson

Day Two

Thursday 28th June, 2018

14.10 | Panel Discussion : Animal Model Systems to Predict Human Translation

13.40 | Biological Therapies for Gliomas - Oncolytic Viruses and Bone Marrow Derived Mesenchymal Stem Cells

Gabriella Campadelli-Fiume
Professor,
University of Bologna

Day One

Wednesday 27th June, 2018

11.40 | Durable Immunotherapeutic Effects and Abscopal Efficacy of a HER2- Retargeted IL12-Armed oHSV

Jean-Simon Diallo
Assistant Professor, Biochemistry, Microbiology & Immunolog
University of Ottawa

Day Two

Thursday 28th June, 2018

09.40 | Small Molecule Enhancers of Oncolytic Immunotherapy

John Bell
Professor of Medicine
Ottawa Health Research Institute

John Bell is an international leader in the development of oncolytic viruses that selectively infect and kill cancer cells, while leaving healthy tissues unharmed. His research lab focuses on the discovery/design of oncolytic viruses, their manufacture and clinical translation.  He is a Scientific Co-founder of Turnstone Biologics which is clinically testing rhabdovirus based oncolytic virus vaccine products and a novel vaccinia virus platform encoding multiple therapeutic transgenes. John is a Senior Scientist at the Ottawa Hospital Research Institute and the Scientific Director of a Canadian National Network (BioCanRx) aimed at translating Anti-Cancer Biotherapeutics from the laboratory into the Clinic.

Pre-Conference Workshop Day

Tuesday 26th June, 2018

09.00 | Identify the Next Generation of Armed Therapeutics in Combination

Day Two

Thursday 28th June, 2018

11.10 | Panel Discussion: Explore Novel Approaches to Identify the Most Rational Combinations

Colin Love
Chief Operating Officer
Replimune

Day One

Wednesday 27th June, 2018

09.40 | Overcoming the Manufacturing Challenges in Taking Novel Oncolytic Immunotherapy Products from Design to Approval

10.10 | Panel Discussion: Strategies to Accelerate Movement into Early Stage Clinical Development with Future Focused Plans for Mature Commercialisation

Akseli Hemminki
Founder, Chief Executive Officer & Chairman of the Board
TILT Biotherapeutics

Day One

Wednesday 27th June, 2018

12.10 | Enabling T-Cell Therapies for Solid Tumors with Armed Oncolytic Adenoviruses

Day Two

Thursday 28th June, 2018

11.10 | Panel Discussion: Explore Novel Approaches to Identify the Most Rational Combinations

Julia Pomoransky
Manager, Manufacturing Sciences & Technology
Turnstone Biologics

Day One

Wednesday 27th June, 2018

10.10 | Panel Discussion: Strategies to Accelerate Movement into Early Stage Clinical Development with Future Focused Plans for Mature Commercialisation

09.10 | Developing a CMC Strategy for Oncolytic Virus based Cancer Immunotherapy

Eric Quemeneur
Executive Vice President
Transgene S.A

Day One

Wednesday 27th June, 2018

14.10 | InvirIO® : Immuno-Armed Oncolytic Vaccinia Viruses to Reprogram the Tumor Microenvironment

10.10 | Panel Discussion: Strategies to Accelerate Movement into Early Stage Clinical Development with Future Focused Plans for Mature Commercialisation

Daniel Katzman
Chief Executive Officer
Unleash Immuno Oncolytics

Day One

Wednesday 27th June, 2018

14.40 | Immunizing CRAd for Carcinoma of the Ovary

Day Two

Thursday 28th June, 2018

14.10 | Panel Discussion : Animal Model Systems to Predict Human Translation

Michael Stein
Executive Chairman
Valo Therapeutics

Day One

Wednesday 27th June, 2018

15.40 | Valo Therapeutics: Reinventing Cancer Immunotherapy

Patrik Erlmann
Head of Research & Development
ViraTherapeutics

Day Two

Thursday 28th June, 2018

14.10 | Panel Discussion : Animal Model Systems to Predict Human Translation

11.40 | VSV-GP Therapy is Effective Though Direct Tumor Lysis and Stimulation of an Anti-Tumor Immune Response

Hideki Kasuya
Director & Professor, Cancer Immune Therapy Center
Nagoya University

Day Two

Thursday 28th June, 2018

10.10 | Overview of the Immunotherapy Combinations with HF10 from Clinical Trial and Basic Research